Last Updated : April 20, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued Sort descending |
|---|---|---|---|---|---|---|
| Lapelga | Pegfilgrastim | Febrile neutropenia | N/A | Complete | ||
| Mvasi | Bevacizumab | mCRC NSCLC Biosimilar | N/A | Complete | ||
| TBC | halobetasol propionate and tazarotene | Psoriasis, moderate to severe plaque | Withdrawn | |||
| Ogivri | Trastuzumab | Withdrawn | ||||
| Zytiga | Abiraterone | Withdrawn | ||||
| TBC | filgrastim | Prevention or treatment of neutropenia in various indications | Cancelled | |||
| Fulphila | pegfilgrastim | Febrile neutropenia in non-myeloid malignancies | N/A | Complete | ||
| Semglee | insulin glargine | Diabetes mellitus, Type 1 & 2 | Withdrawn | |||
| TBC | filgrastim | Cancelled | ||||
| Oncaspar | Pegaspargase | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed |
Last Updated : April 20, 2024